Search Results

You are looking at 1 - 9 of 9 items for :

  • dual-release hydrocortisone x
Clear All
Open access

V Guarnotta, C Di Stefano, A Santoro, A Ciresi, A Coppola and C Giordano

). Once-daily dual-release hydrocortisone (DR-HC) has been demonstrated to provide a cortisol exposure-time profile close to the physiological one. It is characterized by an immediate-release fraction of HC in the outer layer of the tablet and an extended-release

Open access

Filippo Ceccato, Elisa Selmin, Chiara Sabbadin, Miriam Dalla Costa, Giorgia Antonelli, Mario Plebani, Mattia Barbot, Corrado Betterle, Marco Boscaro and Carla Scaroni

(expressed as area under the curve, AUC) in patients with adrenal insufficiency during conventional hydrocortisone (conv-HC) and with dual-release hydrocortisone (DR-HC) compared to healthy controls. conv-HC ( n  = 18) DR-HC ( n  = 18) P conv

Open access

L M Mongioì, R A Condorelli, S La Vignera and A E Calogero

hydrocortisone dose of 15–25 mg ( 8 ). The conventional treatment involves a double or triple administration of glucocorticoid, thus causing a supraphysiological cortisol exposition. Recently, a new once-daily dual-release hydrocortisone formulation has been

Open access

David J F Smith, Hemanth Prabhudev, Sirazum Choudhury and Karim Meeran

crises, whereas excessive replacement puts patients at the risk of Cushingoid symptoms and cardiovascular disease ( 6 , 7 ). In an attempt to mimic circadian rhythmicity, hydrocortisone analogues have been developed, including dual release hydrocortisone

Open access

Marcus Quinkler, Bertil Ekman, Claudio Marelli, Sharif Uddin, Pierre Zelissen, Robert D Murray and on behalf of the EU-AIR Investigators

hydrocortisone group, we excluded patients receiving glucocorticoids other than hydrocortisone and those receiving dual-release hydrocortisone. Matched analysis Patients receiving prednisolone at doses <3 mg/day and >6 mg/day in the prednisolone group

Open access

Kathrin R Frey, Tina Kienitz, Julia Schulz, Manfred Ventz, Kathrin Zopf and Marcus Quinkler

Giampietro A Mazziotti G De ML Giustina A. Bone safety of dual-release hydrocortisone in patients with hypopituitarism . Endocrine 2018 60 528 – 531 . ( https://doi.org/10.1007/s12020-017-1512-1 ) 29313195 10.1007/s12020-017-1512-1

Open access

Kamran Iqbal, Kate Halsby, Robert D Murray, Paul V Carroll and Robert Petermann

trial of a novel hydrocortisone dual-release formulation . Journal of Clinical Endocrinology and Metabolism 2012 97 473 – 481 . ( https://doi.org/10.1210/jc.2011-1926 ) 10.1210/jc.2011-1926 8 Bergthorsdottir R Nilsson AG Gillberg P Ekman B

Open access

Maurício Martins da Silva, Lueni Lopes Felix Xavier, Carlos Frederico Lima Gonçalves, Ana Paula Santos-Silva, Francisca Diana Paiva-Melo, Mariana Lopes de Freitas, Rodrigo Soares Fortunato, Leandro Miranda-Alves and Andrea Claudia Freitas Ferreira

resins, found in the covering of canned food ( 1 ). When submitted to acidic pH or high temperature, the polymer undergoes breakdown of the ester bonds and BPA can be released from the matrix, contaminating food, beverages and environment ( 2 , 3

Open access

Arno Téblick, Lies Langouche and Greet Van den Berghe

hormonal ‘fight or flight’ state is activated by the abundancy of released proinflammatory cytokines, the overwhelming activation of sensory neurons, the release of catecholamines and/or the presence of pathogens in the bloodstream ( 5 , 6 ). Further